Skip to main content
World Today News
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Menu
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Gina N. Shishima: Partner and U.S. Management Vice Chair at Norton Rose Fulbright

Gina N. Shishima: Partner and U.S. Management Vice Chair at Norton Rose Fulbright

November 22, 2026 Newsroom News

Gina N. Shishima serves as Partner and Vice Chair of the United States Management Committee at Norton Rose Fulbright, leading intellectual property strategy for life sciences clients from the firm’s Austin office.

The role places her on both the U.S. Management and Global Executive Committees, positioning her to steer the firm’s domestic operations while coordinating with international leadership. Shishima previously held the posts of U.S. Chief Strategy and Operations Partner, U.S. Head of Intellectual Property, and U.S. Head of the IP Transactions and Patent Prosecution practice, Norton Rose Fulbright reported.

Molecular biology foundation drives patent strategy

Shishima holds a Ph.D. in molecular biology from Princeton University and an A.B. in biochemistry from Columbia University. She earned her J.D. from the University of California, Berkeley School of Law in 1998, where she served on the California Law Review and as associate editor of the Berkeley Technology Law Journal.

That scientific training underpins a practice spanning biomarkers, gene editing, gene therapies, immunotherapy, cell-based therapies, microbiomes, pharmacogenomics, and vaccines. Her prosecution experience extends to medical devices and indications including autoimmune diseases, cancer, cardiovascular, muscular, and neurological conditions, and diabetes.

Prosecution and post-grant leadership

Shishima has served as lead counsel managing international patent portfolios for biopharmaceutical companies, universities, and research hospitals. She has led successful appeals before the Patent Trial and Appeal Board and evaluated inventorship issues across complex portfolios.

Her post-grant work includes serving as lead counsel for a re-examined patent covering commercial pharmacogenomics technology and managing inter partes reviews that resulted in successful invalidation of allegedly infringed claims. She also served as co-counsel in a patent interference matter involving cancer gene therapy in which the opposing party conceded priority.

Litigation and due diligence across high-stakes matters

In litigation, Shishima has provided technical counsel during pre-litigation IP licensing disputes and advised counsel in multiple district court patent cases defending global medical device companies and a ceramic manufacturer in hip implant litigation. The allegedly infringed claims in those cases were invalidated in inter partes reviews.

She served as co-counsel in two DNA genotyping cases involving a patent simultaneously subject to reexamination. Those matters settled favorably after her team obtained a temporary restraining order and preliminary injunction in one case and a favorable Markman ruling in the other. Additional litigation experience includes enforcing patents relating to pharmaceutical compositions and patent matters involving DNA technology.

On the transactional side, Shishima has led due diligence for a global life sciences company involving biotechnology, biopharmaceuticals, and chemical compounds. She counseled a Fortune 500 company and its life science subsidiaries on acquisitions of medical apparatus and medical test companies.

Her experience includes lead counsel roles in due diligence for a multibillion-dollar biotechnology acquisition and for a large company settling a patent infringement lawsuit. She has also rendered noninfringement and invalidity opinions across biopharmaceuticals, diagnostics, and other life science areas.

Recognition spans decades of practice

Shishima received the American Bar Association’s Margaret Brent Women Lawyers of Achievement Award in 2024 and was named a Lawdragon Legend the same year.

Chambers USA has ranked her in Texas Intellectual Property annually from 2014 through 2026. Lawdragon has included her in its 500 Leading Global IP Lawyers (2025–2026), 500 Leading Lawyers in America (2017–2026), and 500 Leading Litigators in America (2022–2027). Texas Super Lawyers has recognized her in intellectual property every year since 2012.

The Best Lawyers in America has honored her in Biotechnology and Life Sciences Practice, Litigation – Patent, and Patent Law continuously since 2007. She was named Austin Lawyer of the Year in both Litigation – Patent and Patent Law for 2025.

IAM Patent 1000 has ranked her nationally and in Texas for prosecution and transactions. The Legal 500 US has recommended her in Intellectual Property: Patents (prosecution, re-examination, post-grant), Healthcare: Life Sciences, and Education across multiple years.

Additional honors include the National Asian Pacific American Bar Association’s Daniel K. Inouye Trailblazer Award (2021), Texas Lawyer’s Texas Trailblazer award (2020), and the Judge David Wellington Chew Award from the Asian Pacific Interest Section of the State Bar of Texas (2017).

Bar admissions and federal practice

Shishima is admitted to the State Bars of Texas and New York. She is registered to practice before the United States Patent and Trademark Office and admitted to the Western and Eastern Districts of Texas, the Southern and Eastern Districts of New York, and the U.S. Court of Appeals for the Federal Circuit.

Active voice in patent policy and profession

Shishima presented on achieving strong IP protection for digital health and precision medicine innovation at the Association of University Technology Managers Annual Meeting in Washington, D.C., on March 4, 2025. She addressed patent protection strategies for AI-enabled inventions in healthcare and life sciences at the Baylor College of Medicine Ventures Commercialization Symposium in Houston on February 18, 2025.

Her recent panel appearances include the Fifth Circuit Judicial Conference on the future of the legal profession (May 10, 2024), an AIPLA Rapid Response Webinar on Amgen v. Sanofi and enablement law (June 13, 2023), and multiple Advanced Patent Law Institute sessions on Section 101 updates and practice tips (2019–2022). She has also spoken on the CRISPR patent saga at the Austin Intellectual Property Law Association (May 23, 2018) and on law firm leadership at NAPABA conventions (2017, 2022).

Shishima co-authored analyses of the U.S. Supreme Court’s rulings on isolated DNA and cDNA patent eligibility for Norton Rose Fulbright publications in June 2013. She authored a chapter on recent developments in inter partes review proceedings for the State Bar of Texas Advanced Intellectual Property Law Course (February 2016) and wrote on diversity in law firm partnership for The National Law Journal (December 8, 2014) and Diversity & The Bar (July/August 2016).

Norton Rose Fulbright traces its British lineage to 1794, when Robert Charsley opened a sole practice in London that evolved through partnerships including Sir Phillip Rose and Henry Elland Norton, and amalgamated with shipping specialist Botterell & Roche in 1960. The firm expanded internationally from Hong Kong in 1976 and grew through combinations with Deacons in Australia (2010), Ogilvy Renault in Canada and Deneys Reitz in South Africa (2011), and Macleod Dixon in Canada (2012).

Its American counterpart began in 1919 when Rufus C. Fulbright and John H. Crooker founded Fulbright & Crooker in Houston; Leon Jaworski joined in 1931, later serving as Watergate special prosecutor in 1973. The two firms merged on June 3, 2013, creating a global practice with more than 3,500 lawyers and other legal professionals in over 50 cities worldwide.

Leadership in bar associations

Shishima serves on the Board of Governors for the National Asian Pacific American Bar Association as Southwest Regional Governor (2011–2013) and Women’s Leadership Committee Co-Chair (present). She is a council member of the Austin Asian American Bar Association, a member of the State Bar of Texas Asian Pacific Interest Section, and serves on the IP Committee of the Asian American Bar Association of New York.

Her memberships include the American Intellectual Property Law Association, Austin Intellectual Property Law Association, Association of University Technology Managers, American Bar Association, and Travis County Bar Association.

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

More on this

  • Lewis Pugh Swims Strait of Hormuz to Highlight War’s Environmental Toll
  • Otaki Declares Severance From Saito After Conviction, Appeal Filed

Related

AIDS, Antibodies, antibody, arrays, Austin, biologics, biosimilars, biotechnology, CAR-T, diagnostics, diversity, dna, gene therapy, immunotherapy, inclusion, infection, Life Sciences, litigation, machine learning, methylation, microbiome, mRNA, Norton, opinions, patent, pharmaceuticals, platform, Stem Cells, technology, therapeutics, vaccine, vaccines

Search:

World Today News

World Today News is your trusted source for global journalism — breaking headlines, in-depth analysis, and reporting from around the world.

Quick Links

  • Privacy Policy
  • About Us
  • Accessibility statement
  • California Privacy Notice (CCPA/CPRA)
  • Contact
  • Cookie Policy
  • Disclaimer
  • DMCA Policy
  • Do not sell my info
  • EDITORIAL TEAM
  • Terms & Conditions

Browse by Location

  • GB
  • NZ
  • US

Connect With Us

© 2026 World Today News. All rights reserved. Your trusted global news source directory.
For contact, advertising, copyright, issues email: [email protected]

Privacy Policy Terms of Service